[Image from Jp Valery on Unsplash]
Across 2021, medtech has seen a wide range of mergers and acquisitions covering several areas of devices, pharmaceuticals and more.Some have gone off without a hitch, while others fell into serious scrutiny as mouthwatering financial figures were revealed and major technologies were acquired.
Here are the 10 biggest mergers and acquisitions in medtech in 2021:
Next>>
The medtech industry hit a slight lull in the early stages of 2021 and, after signs of a rebound, it has soared beyond levels ever before seen.
MassDevice‘s MedTech 100 Index had been building up steam in the month of April, rising from 102.16 points at the beginning of March all the way to 109.39 to end the week before last (April 9). Having only set its previous all-time best of 110.96 on Feb. 15, the industry’s topsy-turvy run gave no indication of which direction it was heading next.
However, after the rise over the past couple of weeks, the industry rode that wave to a new all-time high of 112.25 to end last week on April 16. That represents a 2.6% rise from the previous week’s tally.
Improvements continue to shine a light on the strong position the industry has settled into a year on from the height of the COVID-19 pandemic’s impact on medtech, as the industry has produced an 21.6% rise from the pre-pandemic high of 92.32 (set on Feb. 1…
Amgen (NSDQ:AMGN) announced today that it completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX).
Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021.
Get the full story at our sister site, Drug Delivery Business News.
The medtech industry’s hot start to 2021 has finally come to a full halt after stocks fell harder than they had in more than four months.
MassDevice‘s MedTech 100 index ended the week (March 5) at 103.3 points, marking a -3.1% dip from the 106.65-point mark set one week before (Feb. 26). In less than a month, the fall has been more than seven points from the end-of-week tally of 110.63 points on Feb. 12.
Medtech’s lowest point of the week was on Thursday, March 4, when it fell to 102.85. The overall drop of about five points from the 107.88-point mark set on Monday, March 1, is the largest dip since the index slid from 97.2 to 91.01 between Oct. 23, 2020, and Oct. 30, 2020.
The all-time best for the index was 110.96, set just three days after that. The index had never reached even the 100-point mark before November 2020.
Still, the industry is in much better condition than it was around this time last year. Medtech’s latest mark means …
Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion.
Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release.
Get the full story at our sister site, Drug Delivery Business News.